Literature DB >> 12070334

Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus.

Bruce A Kerwin1, Byeong S Chang, Colin V Gegg, Margherita Gonnelli, Tiansheng Li, Giovanni B Strambini.   

Abstract

The effects of polyethylene glycol (PEG) on protein structure and the molecular details that regulate its association to polypeptides are largely unknown. These issues were addressed using type I soluble tumor necrosis factor receptor (sTNF-RI) as a model system. Changes in solution viscosity established that a truncated form of sTNF-RI bound free PEG in a pH-dependent manner. Above pH 5.3, the viscosity escalated as the pH increased, while no effect occurred below pH 5.0. Conjugation of 2 kD, 5 kD, or 20 kD PEG to the N terminus attenuated the viscosity at the higher pH values. Tryptophan phosphorescence spectroscopy correlated changes in the protein structure about Trp-107, at the C terminus, with the pH-dependent and PEGylation-dependent attenuation of the viscosity. The results indicate that specific interactions between PEG and the truncated form of sTNF-RI are elicited by an increased flexibility of the truncated protein combined perhaps with removal of steric or charge barriers. Covalently bound PEG at the N terminus reduced the protein affinity for the free polymer and induced a more rigid and polar configuration around Trp-107. Deprotonation of His-105, which is perpendicular to Trp-107, was integral to the binding mechanism producing a pH-dependent switching mechanism. These findings stress the importance of surface charge and structural plasticity in determining macromolecular binding affinities and demonstrate the ability of conjugated PEG to modify the localized surface structure in proteins away from the site of conjugation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070334      PMCID: PMC2373643          DOI: 10.1110/ps.0208102

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  32 in total

1.  Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.

Authors:  R B Pepinsky; D J LePage; A Gill; A Chakraborty; S Vaidyanathan; M Green; D P Baker; E Whalley; P S Hochman; P Martin
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

2.  Structures of the extracellular domain of the type I tumor necrosis factor receptor.

Authors:  J H Naismith; T Q Devine; T Kohno; S R Sprang
Journal:  Structure       Date:  1996-11-15       Impact factor: 5.006

3.  Surface modification using silanated poly(ethylene glycol)s.

Authors:  S Jo; K Park
Journal:  Biomaterials       Date:  2000-03       Impact factor: 12.479

4.  A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans.

Authors:  G Molineux; O Kinstler; B Briddell; C Hartley; P McElroy; P Kerzic; W Sutherland; G Stoney; B Kern; F A Fletcher; A Cohen; E Korach; T Ulich; I McNiece; P Lockbaum; M A Miller-Messana; S Gardner; T Hunt; G Schwab
Journal:  Exp Hematol       Date:  1999-12       Impact factor: 3.084

Review 5.  PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.

Authors:  C K Edwards
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

6.  Partitioning and purification of monoclonal antibodies in aqueous two-phase systems.

Authors:  B A Andrews; S Nielsen; J A Asenjo
Journal:  Bioseparation       Date:  1996

7.  Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon.

Authors:  C C Solorzano; A Kaibara; P J Hess; P D Edwards; R Ksontini; A Abouhamze; S McDaniel; J Frazier; D Trujillo; G Kieft; J Seely; T Kohno; M E Cosenza; M Clare-Salzler; S L MacKay; S W Martin; L L Moldawer; C K Edwards
Journal:  J Appl Physiol (1985)       Date:  1998-04

8.  Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol.

Authors:  C R Deible; P Petrosko; P C Johnson; E J Beckman; A J Russell; W R Wagner
Journal:  Biomaterials       Date:  1999-01       Impact factor: 12.479

9.  The application of aqueous two-phase systems to the purification of pharmaceutical proteins from transgenic sheep milk.

Authors:  D P Harris; A T Andrews; G Wright; D L Pyle; J A Asenjo
Journal:  Bioseparation       Date:  1997

10.  A hydrophobic interaction site for lysozyme binding to polyethylene glycol and model contact lens polymers.

Authors:  E L Furness; A Ross; T P Davis; G C King
Journal:  Biomaterials       Date:  1998-08       Impact factor: 12.479

View more
  10 in total

1.  Effects of cavity-forming mutations on the internal dynamics of azurin.

Authors:  Patrizia Cioni; Ellen de Waal; Gerard W Canters; Giovanni B Strambini
Journal:  Biophys J       Date:  2004-02       Impact factor: 4.033

2.  Contribution of TNF-alpha and nuclear factor-kappaB signaling to type 2 iodothyronine deiodinase activation in the mediobasal hypothalamus after lipopolysaccharide administration.

Authors:  Edith Sánchez; Praful S Singru; Gábor Wittmann; Shira S Nouriel; Perry Barrett; Csaba Fekete; Ronald M Lechan
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

3.  Cavity-creating mutations in Pseudomonas aeruginosa azurin: effects on protein dynamics and stability.

Authors:  Edi Gabellieri; Ettore Balestreri; Alvaro Galli; Patrizia Cioni
Journal:  Biophys J       Date:  2008-04-18       Impact factor: 4.033

4.  Effects of sucrose on the internal dynamics of azurin.

Authors:  Patrizia Cioni; Emilia Bramanti; Giovanni B Strambini
Journal:  Biophys J       Date:  2005-03-25       Impact factor: 4.033

Review 5.  PEGylated Human Serum Albumin: Review of PEGylation, Purification and Characterization Methods.

Authors:  Parvin Akbarzadehlaleh; Mona Mirzaei; Mahdiyeh Mashahdi-Keshtiban; Karim Shamsasenjan; Hamidreza Heydari
Journal:  Adv Pharm Bull       Date:  2016-09-25

6.  Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study.

Authors:  Rahul S Rajan; Tiansheng Li; Mohini Aras; Christopher Sloey; Weston Sutherland; Hiromi Arai; Robert Briddell; Olaf Kinstler; Alexis M K Lueras; Yu Zhang; Heather Yeghnazar; Michael Treuheit; David N Brems
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

7.  Conformational transitions provoked by organic solvents in chicken egg ovalbumin: mimicking the local environment.

Authors:  Afshin Iram; Aabgeena Naeem
Journal:  Protein J       Date:  2013-01       Impact factor: 2.371

8.  Anion binding mediated precipitation of a peptibody.

Authors:  Atul Saluja; Shon Crampton; Eva Kras; R Matthew Fesinmeyer; Richard L Remmele; Linda O Narhi; David N Brems; Yatin R Gokarn
Journal:  Pharm Res       Date:  2008-09-27       Impact factor: 4.200

9.  Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition.

Authors:  Navneet Kaur; Prakash Kumar Sinha; Girish Sahni
Journal:  PLoS One       Date:  2019-05-29       Impact factor: 3.240

Review 10.  PEGylated drugs in rheumatology--why develop them and do they work?

Authors:  Thomas McDonnell; Yiannis Ioannou; Anisur Rahman
Journal:  Rheumatology (Oxford)       Date:  2013-08-20       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.